These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children. Author: Wood C, von Baeyer CL, Bourrillon A, Dejos-Conant V, Clyti N, Abitbol V. Journal: Vaccine; 2004 Nov 25; 23(2):127-31. PubMed ID: 15531028. Abstract: The aim of this study was to compare self-reported immediate post-vaccination pain and safety of Priorix versus RORVax in 4- to 6-year-old children receiving their second dose of MMR vaccine, using the Faces Pain Scale-Revised (FPS-R), a validated self-report pain scale recommended by the French National Accreditation Agency and Health Evaluation. A total of 620 children from 28 French pediatricians completed all study procedures. Immediate post-vaccination pain was reported by 17.8% of the subjects in Priorix group (N=309) and by 44.7% of the subjects in RORVax group (N=311) [OR=3.7; P<0.001]. Parents' pain scores correlated significantly with children's scores. The reduction of immediate pain incidence in Priorix group persisted over the 4 post-vaccination days. This study, using a validated self-assessment pain scale, confirmed previous data showing a significantly lower incidence of immediate post-vaccination pain with Priorix as compared to RORVax.[Abstract] [Full Text] [Related] [New Search]